We're excited to announce that we've dosed the first participants in the first denovo designed pharmaceutical to have tissue-selective distribution to bone, MES1022, to accelerate healing of bone fractures. MES1022 is well-positioned to be the first therapy that mimics and enhances the natural processes the body uses to stimulate bone repair and healing.
Mesentech was founded upon 24 years of research starting from observations of the bone anabolic effects of prostaglandins by Dr. Gideon Rodan, the world-renowned scientist who spearheaded development of the osteoporosis drug, Fosamax™.
Many were convinced our target was undruggable due to systemic side-effects that derailed previous efforts by much larger pharmaceutical companies. Today we announce that our team proved not only that that it can be done with this therapeutic, but that tissue-targeting pharmaceuticals is a novel modality to make medicines. We're excited to advance our first candidate into clinical trials.